CL2013000589A1 - Metodo para preparar derivados del acido 3-amino-4-(3,4,5,5-tetrasustituido)-2-oxo-piperidin-1-il)-4-butirico por reaccion entre un acido 3,4-diaminobutanoico y un acido 5-hidroxipentanoico. - Google Patents

Metodo para preparar derivados del acido 3-amino-4-(3,4,5,5-tetrasustituido)-2-oxo-piperidin-1-il)-4-butirico por reaccion entre un acido 3,4-diaminobutanoico y un acido 5-hidroxipentanoico.

Info

Publication number
CL2013000589A1
CL2013000589A1 CL2013000589A CL2013000589A CL2013000589A1 CL 2013000589 A1 CL2013000589 A1 CL 2013000589A1 CL 2013000589 A CL2013000589 A CL 2013000589A CL 2013000589 A CL2013000589 A CL 2013000589A CL 2013000589 A1 CL2013000589 A1 CL 2013000589A1
Authority
CL
Chile
Prior art keywords
acid
piperidin
oxo
tetrasubstituted
amino
Prior art date
Application number
CL2013000589A
Other languages
English (en)
Inventor
Bong Chan Kim
Kyu Young Kim
Hee Bong Lee
Ji Eun An
Kyu Woong Lee
Original Assignee
Lg Life Science3S Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Life Science3S Ltd filed Critical Lg Life Science3S Ltd
Publication of CL2013000589A1 publication Critical patent/CL2013000589A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Hydrogenated Pyridines (AREA)
  • Catalysts (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Método para la preparación de un compuesto derivado de ácido 2-oxo-piperidin-1-il-butírico.
CL2013000589A 2010-09-03 2013-03-01 Metodo para preparar derivados del acido 3-amino-4-(3,4,5,5-tetrasustituido)-2-oxo-piperidin-1-il)-4-butirico por reaccion entre un acido 3,4-diaminobutanoico y un acido 5-hidroxipentanoico. CL2013000589A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20100086619 2010-09-03

Publications (1)

Publication Number Publication Date
CL2013000589A1 true CL2013000589A1 (es) 2013-07-12

Family

ID=45023417

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013000589A CL2013000589A1 (es) 2010-09-03 2013-03-01 Metodo para preparar derivados del acido 3-amino-4-(3,4,5,5-tetrasustituido)-2-oxo-piperidin-1-il)-4-butirico por reaccion entre un acido 3,4-diaminobutanoico y un acido 5-hidroxipentanoico.

Country Status (32)

Country Link
US (1) US8741927B2 (es)
EP (1) EP2611776B1 (es)
JP (1) JP5705985B2 (es)
KR (1) KR101378984B1 (es)
CN (1) CN103080088B (es)
AP (1) AP3270A (es)
AR (1) AR082881A1 (es)
AU (1) AU2011296767B2 (es)
BR (1) BR112013004988B1 (es)
CA (1) CA2810393C (es)
CL (1) CL2013000589A1 (es)
CO (1) CO6700826A2 (es)
DK (1) DK2611776T3 (es)
EA (1) EA022500B1 (es)
EC (1) ECSP13012471A (es)
ES (1) ES2607089T3 (es)
HU (1) HUE032484T2 (es)
IL (1) IL224954B (es)
MA (1) MA34490B1 (es)
MX (1) MX2013002277A (es)
MY (1) MY157423A (es)
NZ (1) NZ607694A (es)
PE (1) PE20131128A1 (es)
PH (1) PH12013500343A1 (es)
PL (1) PL2611776T3 (es)
PT (1) PT2611776T (es)
SG (1) SG188329A1 (es)
SI (1) SI2611776T1 (es)
TW (1) TWI438188B (es)
UA (1) UA107721C2 (es)
UY (1) UY33589A (es)
WO (1) WO2012030106A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2995612A1 (en) * 2014-09-12 2016-03-16 Université de Strasbourg Novel non-natural amino acids, their process of preparation and uses thereof
KR102068754B1 (ko) * 2017-04-20 2020-01-21 주식회사 엘지화학 의약품 합성용 중간체 화합물의 제조 방법
WO2019066578A1 (ko) * 2017-09-28 2019-04-04 주식회사 엘지화학 의약품 합성용 중간체 화합물의 제조 방법
CN111164071A (zh) * 2017-09-28 2020-05-15 株式会社Lg化学 用于合成药物的中间体化合物的制备方法
WO2019098551A1 (ko) * 2017-11-16 2019-05-23 주식회사 엘지화학 의약품 합성용 중간체 화합물의 제조 방법
CN111247127B (zh) * 2017-11-16 2024-02-06 株式会社Lg化学 用于合成药物的中间体化合物的生产方法
CN113861061A (zh) * 2021-10-25 2021-12-31 成都市科隆化学品有限公司 一种不含无机铵盐的氨基酸酰胺盐酸盐及其合成方法
CN117682981A (zh) * 2022-09-02 2024-03-12 中国科学院大连化学物理研究所 一种吉格列汀药物前体的制备方法
KR20250155700A (ko) 2024-04-24 2025-10-31 주식회사 다산제약 제미글립틴 산부가염 제조방법 및 이를 유효성분으로 포함하는 dpp-4 저해용 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456768A (en) * 1980-10-08 1984-06-26 The University Of Chicago Chemical synthesis
US5556982A (en) 1985-01-14 1996-09-17 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
DE3705272A1 (de) * 1987-02-19 1988-09-01 Basf Ag Verfahren zur reduktion von mono- und dicarbonsaeuren
US5417023A (en) * 1993-12-27 1995-05-23 Mandish; Theodore O. Building panel apparatus and method
JP2003528097A (ja) * 2000-03-17 2003-09-24 ブリストル−マイヤーズ スクイブ ファーマ カンパニー マトリックスメタロプロテアーゼおよびＴＮＦ−α阻害剤としてのβ−アミノ酸誘導体
TWI357902B (en) * 2005-04-01 2012-02-11 Lg Life Science Ltd Dipeptidyl peptidase-iv inhibiting compounds, meth
US20100210706A1 (en) * 2006-08-09 2010-08-19 Smithkline Beecham Corporation Pyrrolidinone anilines as progesterone receptor modulators
KR20080071476A (ko) * 2007-01-30 2008-08-04 주식회사 엘지생명과학 신규한 디펩티딜 펩티데이즈 ｉｖ(ｄｐｐ-ｉｖ) 저해제
EP2220086A4 (en) * 2007-12-21 2010-12-22 Lg Life Sciences Ltd DIPEPTIDYLPEPTIDASE IV-INHIBITABLE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREFOR AS ACTIVE AGENT

Also Published As

Publication number Publication date
EP2611776A2 (en) 2013-07-10
EP2611776B1 (en) 2016-09-21
EP2611776A4 (en) 2014-08-20
DK2611776T3 (en) 2017-01-09
PH12013500343A1 (en) 2015-01-23
HUE032484T2 (en) 2017-09-28
EA201390336A1 (ru) 2013-07-30
TW201213297A (en) 2012-04-01
ES2607089T3 (es) 2017-03-29
SG188329A1 (en) 2013-04-30
TWI438188B (zh) 2014-05-21
AP3270A (en) 2015-05-31
PE20131128A1 (es) 2013-10-18
PT2611776T (pt) 2016-12-20
BR112013004988A2 (pt) 2016-05-31
JP5705985B2 (ja) 2015-04-22
KR20120060139A (ko) 2012-06-11
AU2011296767A1 (en) 2013-03-14
CN103080088B (zh) 2014-09-24
AR082881A1 (es) 2013-01-16
MX2013002277A (es) 2013-05-22
ECSP13012471A (es) 2013-04-30
BR112013004988B1 (pt) 2020-07-28
NZ607694A (en) 2015-08-28
IL224954B (en) 2018-11-29
PL2611776T3 (pl) 2017-06-30
KR101378984B1 (ko) 2014-03-27
CO6700826A2 (es) 2013-06-28
UA107721C2 (ru) 2015-02-10
CA2810393C (en) 2016-04-12
CA2810393A1 (en) 2012-03-08
SI2611776T1 (sl) 2017-03-31
EA022500B1 (ru) 2016-01-29
CN103080088A (zh) 2013-05-01
AP2013006763A0 (en) 2013-03-31
UY33589A (es) 2011-12-01
US8741927B2 (en) 2014-06-03
AU2011296767B2 (en) 2015-04-23
WO2012030106A3 (en) 2012-05-18
WO2012030106A2 (en) 2012-03-08
MA34490B1 (fr) 2013-08-01
MY157423A (en) 2016-06-15
HK1184787A1 (en) 2014-01-30
JP2013543484A (ja) 2013-12-05
US20130165659A1 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
CL2013000589A1 (es) Metodo para preparar derivados del acido 3-amino-4-(3,4,5,5-tetrasustituido)-2-oxo-piperidin-1-il)-4-butirico por reaccion entre un acido 3,4-diaminobutanoico y un acido 5-hidroxipentanoico.
JOP20210065B1 (ar) andnbsp;andnbsp;andnbsp;5-فلورو-H1 بيرازولوبيريدينات مستبدلة andnbsp;في شكل متبلور
DOP2012000105A (es) Compuestos de espiropiperidina y uso farmaceutico del mismo para tratar la diabetes
PH12015500263A1 (en) New bicyclic derivatives
MX2012005358A (es) Procedimiento para la preparacion de etexilato de dabigatran.
MX2010007587A (es) Compuestos que comprenden un grupo ciclobutoxi.
PH12013500083A1 (en) Method for producing hydraulic powder
MX2011008864A (es) Tetrahidroazolopirazinas sulfoniladas y su uso como productos medicinales.
GEP20186903B (en) Chloro-pyrazine carboxamide derivatives useful for the treatment of diseases favoured by insufficient mucosal hydration
TN2014000095A1 (en) Pharmaceutical compositions
PH12015502546B1 (en) 3-(4-isobutyl-2-methylphenyl) propanal as perfume ingredient
PH12013500554A1 (en) Process for preparing pan-cdk inhibitors of the formula (i) and intermediates in the preparation
MX392317B (es) Proceso para la preparación de etilenglicol a partir de azúcares.
UY34767A (es) Inhibidores cíclicos del enlace éter de dgat1
CL2012000560A1 (es) Procedimiento de preparacion del compuesto intermediario acido 3-oxo-tetrahidrotiofeno-2-carboxilico, utiles en la preparacion de dihidrotienopirimidinas (divisional de la solicitud 3095-08).
MX384794B (es) Proceso para la preparacion de 5-fluoro-1h-pirazoles a partir de hexafluoropropeno.
MX347348B (es) Sintesis de derivados de 2-carboxamida-cicloamino-urea.
IN2012DN05081A (es)
PH12014501367A1 (en) Processes for making magnolol and derivatives thereof
CL2014002029A1 (es) Método para preparar un compuesto de formula 1 mediante la reacción de adición de michael , usando agua o acido o una mezcla de los mismos como aditivo, entre un compuesto de formula 2 y un compuesto de formula 3 en presencia de polvo de cobre.
MA39877A (fr) Formes solides d'un composé pharmaceutiquement actif
MX356846B (es) Compuestos de metanotiona que tienen actividad antiviral.
MY170662A (en) New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
GB2564185A (en) Process for the preparation of derivatives of benzodioxole
IN2012DN00346A (es)